FDA accepts priority review of CSL-uniQure hemophilia B gene therapy; Fosun Pharma nets another deal
The first potential gene therapy for hemophilia B has gotten one step closer to reaching patients as the FDA has accepted CSL Behring’s BLA for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
